# A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

> **NCT06112379** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1902 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dato-DXd
- **DRUG:** Durvalumab
- **DRUG:** Pembrolizumab
- **DRUG:** Doxorubicin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Capecitabine
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT06112379
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2028-11-20
- **Final completion:** 2032-09-23
- **Target enrollment:** 1902 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06112379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06112379, "A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06112379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*